Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly EBITDA Margin of 10173.74% for Q3 2025, down 879713.0% year-over-year from N/an in Q3 2024, and up 43.78% quarter-over-quarter from 18096.89% in Q2 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 10173.74% for Q3 2025.
- In Q3 2025, EBITDA Margin fell 879713.0% year-over-year to 10173.74%; the TTM figure through Sep 2025 stood at 4504.27% (down 295031.0% YoY), while the FY2024 annual figure was 1633.74%, up 7093.0% from the prior year.
- EBITDA Margin for Q3 2025 stood at 10173.74%, up from 18096.89% in the prior quarter.
- The five-year high for EBITDA Margin was 703.67% in Q3 2022, with the low at 18096.89% in Q2 2025.
- The 4-year median for EBITDA Margin is 1705.52% (2023), against an average of 3625.17%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 63438 bps in 2024, then slumped 1690505 bps in 2025.
- Dianthus Therapeutics' EBITDA Margin stood at 910.04% in 2022, then plunged by 234 bps to 3041.31% in 2023, then grew by 21 bps to 2406.94% in 2024, then slumped by 323 bps to 10173.74% in 2025.
- Business Quant data shows DNTH's EBITDA Margin at 10173.74% in Q3 2025, 18096.89% in Q2 2025, and 2764.75% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -10,173.74% |
| Jun 30, 2025 | -18,096.89% |
| Mar 31, 2025 | -2,852.71% |
| Dec 31, 2024 | -2,406.94% |
| Sep 30, 2024 | -1,376.61% |
| Jun 30, 2024 | -1,191.84% |
| Mar 31, 2024 | -2,041.65% |
| Dec 31, 2023 | -2,835.01% |
| Sep 30, 2023 | -1,705.52% |
| Jun 30, 2023 | -1,177.60% |
| Mar 31, 2023 | -1,536.60% |
| Dec 31, 2022 | -910.04% |
| Sep 30, 2022 | -703.67% |